新闻 – 维梧新闻2019-10-24T03:43:23-07:00


Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

8月 26th, 2021|

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

1月 9th, 2021|

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

11月 8th, 2018|

Terns Pharmaceuticals与上海拓臻生物科技有限公司 完成8000万美元B轮融资,用于推进NASH和癌症药物的研发

10月 30th, 2018|